Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced on Friday that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Opdivo (nivolumab) in combination with chemotherapy for neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in patients with tumour cell PD-L1 expression ≥1%.
This recommendation was based on Phase 3 CheckMate -816 trial results, showing improved event-free survival and pathologic complete response compared to chemotherapy alone when given before surgery.
If approved, Opdivo with chemotherapy would be the first neoadjuvant immunotherapy-based option for NSCLC patients in the European Union.
The CHMP recommendation will now be reviewed by the European Commission.
Opdivo has already been approved for neoadjuvant treatment of resectable NSCLC in multiple countries, including the United States, Japan and China. Opdivo-based treatments have demonstrated efficacy in neoadjuvant or adjuvant treatment of lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma.
Carisma Therapeutics' CT-0525 IND application receives US FDA approval
Orexo's OX124 New Drug Application accepted for review by US Food and Drug Administration
GE HealthCare expands Critical Care Suite with FDA-cleared Pneumothorax detection algorithm
NanoVibronix initiates clinical study for UroShield at University of Michigan
Acrivon Therapeutics secures FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Orexo's opioid overdose rescue medication, OX124, gains FDA acceptance for review
SpringWorks Therapeutics' Ogsiveo tablets receive US FDA approval
RedHill Biopharma granted five years' market exclusivity for Talicia by US FDA
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
Genelux secures FDA Fast Track designation for Olvi-Vec in ovarian cancer
EMA accepts Valneva's chikungunya vaccine application for accelerated assessment
Dupixent shows significant COPD exacerbation reduction in Phase 3 trial, accelerating FDA submission
Everest Medicines Nefecon receives Chinese regulatory approval